Dairy intake has been associated with increased risk of advanced prostate cancer. Two US cohort studies reported increased prostate cancer-specific mortality with increased high-fat milk intake. We examined whether dairy and related nutrient intake were associated with prostate cancer progression in a Swedish patient population with high dairy consumption. We prospectively followed 525 men with newly diagnosed prostate cancer (diagnosed 1989-1994). We identified and confirmed deaths through February 2011 (n 5 222 prostate cancer-specific, n 5 268 from other causes). Cox proportional hazards regression was used to calculate hazard ratios (HR) and 95% confidence intervals (CI) for the associations between food or nutrient intake and prostate cancer-specific death. On average, patients consumed 5.0 servings/day of total dairy products at diagnosis. In the whole population, high-fat milk intake was not associated with prostate cancer-specific death (95% CI: 0.78, 2.10; p-trend 5 0.32; multivariate-adjusted model). However, among patients diagnosed with localized prostate cancer, compared to men who consumed <1 servings/day of high-fat milk, those who drank 3 servings/day had an increased hazard of prostate cancer mortality (HR 5 6.10; 95% CI: 2.14, 17.37; p-trend 5 0.004; multivariate-adjusted model). Low-fat milk intake was associated with a borderline reduction in prostate cancer death among patients with localized prostate cancer. These associations were not observed among patients diagnosed with advanced stage prostate cancer. Our data suggest a positive association between high-fat milk intake and prostate cancer progression among patients diagnosed with localized prostate cancer. Further studies are warranted to investigate this association and elucidate the mechanisms by which high-fat milk intake may promote prostate cancer progression.
Dairy intake has been associated with increased risk of advanced prostate cancer. Two US cohort studies reported increased prostate cancer-specific mortality with increased high-fat milk intake. We examined whether dairy and related nutrient intake were associated with prostate cancer progression in a Swedish patient population with high dairy consumption. We prospectively followed 525 men with newly diagnosed prostate cancer (diagnosed 1989-1994) . We identified and confirmed deaths through February 2011 (n 5 222 prostate cancer-specific, n 5 268 from other causes). Cox proportional hazards regression was used to calculate hazard ratios (HR) and 95% confidence intervals (CI) for the associations between food or nutrient intake and prostate cancer-specific death. On average, patients consumed 5.0 servings/day of total dairy products at diagnosis. In the whole population, high-fat milk intake was not associated with prostate cancer-specific death (95% CI: 0.78, 2.10; p-trend 5 0.32; multivariate-adjusted model). However, among patients diagnosed with localized prostate cancer, compared to men who consumed <1 servings/day of high-fat milk, those who drank 3 servings/day had an increased hazard of prostate cancer mortality (HR 5 6.10; 95% CI: 2.14, 17.37; p-trend 5 0.004; multivariate-adjusted model). Low-fat milk intake was associated with a borderline reduction in prostate cancer death among patients with localized prostate cancer. These associations were not observed among patients diagnosed with advanced stage prostate cancer. Our data suggest a positive association between high-fat milk intake and prostate cancer progression among patients diagnosed with localized prostate cancer. Further studies are warranted to investigate this association and elucidate the mechanisms by which high-fat milk intake may promote prostate cancer progression.
Background
Among European men, prostate cancer is the most common cancer and the third leading cancer cause of death. 1 In Sweden, 24% of prostate cancer patients die from the disease. 2 In countries where prostate-specific antigen screening (PSA) is more widespread, such as the United States, prostate cancer case-fatality rates are lower. 3 Thus, it is important to identify modifiable factors that might drive prostate cancer progression as well as factors that influence mortality overall. Many studies have found that higher dairy intake, particularly high-fat dairy, is associated with aggressive or lethal prostate cancer. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Several other studies observe no association, [15] [16] [17] [18] [19] [20] [21] but the majority does not distinguish between low and high-fat dairy products. 20 This is critical, as there is wide variation in nutritional composition across dairy products, and these components may influence disease progression differently. For example, whole milk has an approximately 40-fold greater saturated fat content compared to skim milk. 22 To date, only five studies have examined dairy intake and prostate cancer progression after diagnosis; 8, 10, [23] [24] [25] all found that dairy, particularly high-fat dairy, is associated with increased prostate cancer-specific mortality. However, these studies were all conducted within just two demographically similar US cohorts. Dairy intake may promote prostate cancer progression through several potential mechanisms. Calcium and phosphorous, both abundant in dairy products, may lower levels of 1,25(OH)2D, a form of vitamin D that has been shown to inhibit prostate carcinogenesis and promote apoptosis. 26, 27 Dairy and milk intake also increase circulating levels of insulin-like growth factor 1 (IGF1), 28, 29 which are associated with higher prostate cancer risk. 30, 31 In addition, saturated fat, as in high-fat dairy products, may worsen prostate cancer survival. 30 Consequently, it is likely that both type and amount of dairy intake play a role in prostate cancer progression.
To further examine the association between dairy intake and prostate cancer progression, we followed a populationbased cohort of prostate cancer patients in € Orebro County, Sweden. We investigated the associations between total, highfat and low-fat dairy, total, high-fat, low-fat, and sour milk, butter, cheese, calcium, phosphorous and vitamin D and prostate cancer progression. We hypothesized that high-fat milk intake was associated with progression, based on previous studies. 8, 24, 25, 32 Because localized cases may be more susceptible than advanced cases to diet and lifestyle factors, we stratified analyses by stage at diagnosis (localized, advanced). We also investigated the association between high-fat milk intake 20 years prior to diagnosis and prostate cancer-specific and overall mortality.
Subjects and Methods

Study population
Our study population includes 525 prostate cancer patients from a case-control study in € Orebro County, Sweden. 7, 33, 34 Recruitment first occurred between January 1989 and September 1991, and again between May 1992 and July 1994. All participants were men born in Sweden and were <80 years old at enrollment, living in € Orebro, and newly diagnosed with prostate cancer.
Ascertainment of diagnostic and clinical factors
Most participants were diagnosed following prostate-related symptoms, as prostate cancer screening did not occur in € Orebro County at that time. All cases were confirmed by a study pathologist and treated at one of three local hospitals. Of the recruited cases, 81% (n 5 525) participated; 12% refused and 7% were too ill or died before the interview (described below). Tumor stage was assigned according to the World Health Organization (WHO, 1980) TNM classification system 35, 36 (staging used at time of recruitment and diagnosis); localized if confined to the prostate at diagnosis (clinical stage T2 and M0) or advanced if it spread through the capsule or metastasized (clinical stage T3 and/or M1). If necessary, skeletal scintigraphy and radiography were used to assess skeletal metastases. 34 Medical record review provided primary treatment information. The study was approved by the ethical review board in Uppsala University, Sweden.
Assessment of diet and other covariates
Self-administered questionnaires including a 68-item validated food-frequency questionnaire (FFQs) were distributed at enrollment. Most were completed within 3 months of diagnosis, 34 thus reflecting dietary intake the year prior to diagnosis.
The FFQ captured major foods in the Swedish diet and was used to calculate daily energy intake and nutrient values. For each item, the consumption frequency during the previous year was multiplied by the age-specific standard portion size 37 and by the item's nutrient content. Validation details are described elsewhere. 34 The FFQ included 16 dairy products (0.5% fat, 1.5%, 3% and 4% milk, 0.5% and 3% sour milk, Kefir, 0.5% and 3% yoghurt, coffee cream, cream, cottage cheese, sour cream and ice cream). We examined the following categories of dairy products, in servings per day: total dairy (sum of all 16 dairy products), total milk (sum of 4 milk products), high-fat milk (sum of 3% and 4% milk), low-fat milk (sum of 0.5% and 1.5% milk), sour milk (sum of 0.5% and 3% sour milk, 0.5% and 3% yoghurt and Kefir), cheese, butter (butter or bregott), calcium (mg/day), phosphorous (mg/day) and vitamin D (lg/day). Note that milk intake does not include sour milk unless otherwise indicated. Butter intake was estimated from questions about sandwich fat. Participants indicated the type of sandwich fat they typically used, thickness of spread, and slices of bread per day. We multiplied percent dairy in sandwich fat (butter: 100% dairy; bregott: 75% dairy) by thickness of spread (light: 5 g, medium: 10 g, heavy: 20 g) by slices of bread per day, and divided the product by 10 g, a standard serving size. Margarine contains no dairy, so it was not included. Nutrient intakes were calculated based on reported intake of foods items containing these nutrients as described above.
We were also interested in the effects of long-term dairy consumption on prostate cancer-specific and overall mortality. In addition to current intake, participants were asked to recall their average intake 20 years ago through an abbreviated 20-item FFQ. We looked at past consumption, in servings/day, of total milk, high-fat milk and low-fat milk.
What's new? Dairy intake has been associated with an increased risk of advanced prostate cancer. In this prospective European study, the authors found that drinking high-fat milk increased the risk of dying from prostate cancer by as much as 600% in patients with localized prostate cancer. Low-fat milk was not associated with such an increase in risk. Further studies are needed to clarify this association, and to elucidate the mechanism(s) by which high-fat milk intake may promote prostate-cancer progression. For patients diagnosed during the first recruitment period, in-home interviews were conducted to gather information on family history of cancer, smoking status, alcohol consumption and anthropometric measures. Self-administered supplemental questions were included in the FFQ mailing for cases diagnosed during the second period.
Ascertainment of outcome
Unique national registration numbers are assigned to each Swedish resident, permitting linkage across all nationwide health registries. The Swedish Death Registry has >99% coverage of all deaths in Sweden, and identified dates of death. A committee of study urologists -Ove Andren, Sven-Olof Andersson and Jan-Erik Johansson -then reviewed medical records to determine cause of death. Follow-up for death was complete through March 2011.
Statistical analysis
Cox proportional hazards regression was used to calculate multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) for all associations between specific dairy product or nutrient intakes and time to prostate cancer mortality or overall mortality. The intake categories were the referents. To test for linear trend across categories, we modeled the median value of each intake category (servings/day) or nutrient quartile as a continuous variable in a multivariable model. Follow-up time was defined as date of cancer diagnosis to date of death or end of follow-up (March 1, 2011). Four participants missing information on height and BMI were assigned median values.
Our primary analyses investigated the association between intake of dairy products and nutrients (total, high-fat and low-fat dairy; total, high-fat and low-fat milk; butter; cheese; calcium; phosphorous; Vitamin D) and prostate cancerspecific and overall mortality. All multivariable models adjust for age at diagnosis [41-64, 65-69, 70-74 and 75-79 years), calendar year of diagnosis (1989-1991 and 1992-1994) , nonalcohol energy intake (continuous), height (continuous), BMI (continuous), smoking status (never, former, current or missing) and alcohol consumption (nondrinker, <55 g/wk and 55 g/wk). Fully adjusted models additionally adjust for tumor grade (well, moderately or poorly differentiated), family history of prostate cancer in father or brother (yes or no) and primary treatment (watchful waiting, hormones, prostatectomy or other). In secondary analyses, we mutually adjust low-fat and high-fat milk for each other.
To explore our hypothesis that variations in diet may have a stronger effect on disease progression and mortality among men with localized prostate cancer, we examined associations between dairy items and mortality for localized and advanced diagnoses separately. We formally tested for effect modification by conducting a likelihood ratio test with 1 degree of freedom, comparing each multivariable model to a model adding an interaction term between the median value for each dairy item category (continuous) and stage at diagnosis. We also investigated whether the relative proportion of low-fat versus high-fat milk intake was associated with mortality among milk drinkers. We further examined whether past (20 years prior to diagnosis) high-fat milk intake was associated with mortality outcomes.
p-Values of <0.05 indicates statistical significance. All statistics were calculated using SAS (version 9.3; SAS Institute, Inc., Cary, NC). We checked the proportional hazards assumption by including an interaction term between the median item of each dairy item category (continuous) and follow-up time (continuous) to each of the fully adjusted multivariable models presented in Table 2 (Model 2). The proportional hazards assumption was met for every model. 
Results
Population characteristics
During up to 20 years of follow-up, 490 of 525 participants died (>93%); 222 died of prostate cancer and no one was lost to follow-up. 44% were diagnosed with localized prostate cancer, and 11% had poorly differentiated tumors. The mean age at diagnosis was 70.7 years and mean BMI was 25.9 kg/ m 2 , which is representative of the male Swedish population at this time.
38 23% men were current smokers, and among the 52% who drank alcohol, median intake was 55 g (about 4 drinks) per week. Men with high dairy intake were more likely to have clinical stage T1 at diagnosis, less likely to (1989-1991 and 1992-1994) , non-alcohol energy intake (continuous), height (continuous), BMI at diagnosis (continuous), smoking status (never, former, current or missing) and alcohol consumption (nondrinker, <55 g/wk and 55 g/wk). 2 Additionally adjusted for tumor grade (well, moderately or poorly differentiated), family history of prostate cancer in father or brother (yes or no) and primary treatment (watchful waiting, hormones, prostatectomy or other). 3 Total Dairy 5 sum of 0.5%, 1.5%, 3% and 4% milk, 0.5% and 3% sour milk, Kefir, 0.5% and 3% yoghurt, coffee cream, cream, sour cream, cheese, ice cream, butter and cottage cheese. High-fat dairy 5 sum of 3% and 4% milk, 3% sour milk, Kefir, 3% yoghurt, coffee cream, cream, sour cream, butter, cheese and ice cream. Low-fat dairy 5 sum of 0.5% and 1.5% milk, 0.5% sour milk, 0.5% yoghurt and cottage cheese. 4 Total milk 5 sum of 0.5%, 1.5%, 3% and 4% milk. Sour milk 5 sum of 0.5% and 3% sour milk, 0.5% and 3% yoghurt and Kefir. High-fat milk 5 sum of 3% and 4% milk. Low-fat milk 5 sum of 0.5% and 1.5% milk.
drink alcohol, and had higher intakes of total energy, vitamin D and phosphorous. Dairy intake did not vary materially according to other factors (Table 1) . At diagnosis, patients consumed an average of 5.0 servings/day of total dairy products (including 2.0 of milk products, 0.8 of high-fat milk, 1.2 of low-fat milk) ( Table 2) . 20 years prior to diagnosis, patients consumed an average of 2.9 servings/day of milk products, which was almost entirely high-fat. 2 Total milk 5 sum of 0.5%, 1.5%, 3% and 4% milk. High-fat milk 5 sum of 3% and 4% milk. Low-fat milk 5 sum of 0.5% and 1.5% milk. 3 Cox proportional hazards regression model adjusted for age at diagnosis (41-64, 65-69, 70-74 and 75-79 years), calendar year of diagnosis (1989-1991 and 1992-1994) , non-alcohol energy intake (continuous), height (continuous), BMI at diagnosis (continuous), smoking status (never, former, current or missing), alcohol consumption (nondrinker, <55 g/wk and 55 g/wk), tumor grade (well, moderately or poorly differentiated), family history of prostate cancer in father or brother (yes or no) and primary treatment (watchful waiting, hormones, prostatectomy or other). 4 High-fat milk additionally adjusted for low-fat milk and vice-versa.
All cases
Among 525 cases (4,075 person years), total dairy intake was not significantly associated with increased prostate cancer mortality (6 vs Table 4 ). In addition, among those who drank 1 serving of total milk per day, drinking more highfat milk than low-fat milk, regardless of the amount, was associated with an increased hazard of both prostate cancerspecific (p 5 0.03) and overall (p 5 0.05) mortality (Table 4) . Previous high-fat milk intake was not associated with prostate cancer-specific or overall mortality among men with localized prostate cancer (Supplemental Table 2 ).
Advanced cases
In contrast to our findings for localized cases, high-fat milk intake was not associated with prostate cancer mortality for 295 men with advanced prostate cancer (1,752 person years) ( Table 4) . Butter was associated with increased risk of prostate cancer-specific mortality (3 vs. <1 servings/day: 1.69, 1.06-2.69, p-trend 5 0.05; multivariate adjusted); total dairy intake was not significantly associated with risk (6 vs. <3 servings/day: 1.66, 0.98-2.81, p-trend 5 0.13; multivariate adjusted). Total dairy and low-fat milk intake were associated with increased overall mortality (Supplemental Table 1 ). When formally testing for interaction, stage at diagnosis was a significant effect modifier for the association between dairy product and prostate cancer mortality for high-fat milk (p 5 0.01), low-fat milk (p 5 0.01) and low-fat dairy (p 5 0.02). However, in analyses stratified by stage at diagnosis, neither low-fat milk nor low-fat dairy was significantly associated with prostate cancer mortality in either subset.
Discussion
The association between high-fat milk intake and increased prostate cancer mortality among men with localized prostate cancer is noteworthy given the consistency with previous USbased studies. 8, [23] [24] [25] Our hypothesis that dietary factors have the strongest effect on localized cancer holds, but we also found that higher dairy intake was not significantly associated with increased prostate cancer and overall mortality among men with advanced prostate cancer. Butter was significantly associated with increased risk of prostate cancer mortality. While results were not significant, it may be advisable for all prostate cancer patients to decrease dairy consumption, although further research is needed. Our findings are consistent with analyses from the Health Professionals Follow-up Study (HPFS) and the Physicians' Health Study (PHS), the only two other populations used to investigate dairy intake and prostate cancer mortality. A 2006 HPFS analysis found that increased post-diagnostic milk intake was associated with only marginally increased prostate cancer progression, but follow-up time was limited (mean follow-up time 5 6.4 years) and progression was defined as biochemical recurrence or metastasis, which is only a proxy for prostate cancer death. 23 A subsequent HPFS analysis with longer follow-up and greater statistical power found that whole milk intake was associated with increased risk of lethal prostate cancer and biochemical recurrence among men diagnosed with localized prostate cancer. 8 In PHS, pre-diagnostic whole milk intake was associated with increased prostate cancer mortality. Although the authors did not explicitly stratify by stage, the association was stronger among cases diagnosed after the introduction of widespread PSA screening compared to those diagnosed before, and these later diagnoses were much more likely to be localized. 24 Another PHS analysis found that post-diagnostic intake of total high-fat and total low-fat dairy were positively associated with overall mortality, and marginally associated with prostate cancer-specific mortality. The investigators did not stratify on stage at diagnosis. 25 The consistency of these findings across populations with very different dairy consumption levels (average servings/day of total dairy 5 2.0 in PHS, 1.7 in HPFS, 5.0 in € Orebro) and diagnostic practices (PSA screening) provides persuasive evidence. Although the strongest findings are for high-fat milk, there is some evidence that total high-fat dairy products may be associated with increased prostate cancer-specific and overall mortality. It is possible that the weaker associations for other high-fat dairy items reflect lower intake levels.
Several mechanisms may account for these associations. High-fat milk is high in saturated fat, which is associated with increased risk of prostate cancer 11 and biochemical recurrence. 30 While it is possible that something unique to milk increases progression, we also observe an elevated (but non-significant) risk of prostate cancer mortality among men with localized prostate cancer with increasing high-fat dairy intake, and total dairy intake was associated with increased risk of prostate cancer mortality among men with advanced prostate cancer. As hypothesized, it is possible that increased circulating IGF-1 from dairy intake may promote progression. The finding that low-fat dairy may decrease risk of prostate cancer mortality among men with localized stage at diagnosis should be interpreted with caution. Compared to advanced disease, localized prostate cancer is probably more susceptible to lifestyle factors. Because low-fat milk is typically considered healthier, low-fat milk consumers may engage in other healthy behaviors that prevent progression. Furthermore, our results show that low-fat milk consumption may elevate the risk of overall mortality among men with advanced prostate cancer.
We did not observe any associations for past dairy intake. This may be because this exposure window is too early to effect prostate cancer progression. It is also possible that there was high misclassification due to recall error, which would bias the results.
It does not appear that calcium or phosphorous from dairy products play a role in prostate cancer progression. Calcium's carcinogenic effect may be restricted to early stages of cancer progression. It is possible that post-diagnostic calcium intake may suppress parathyroid hormone levels and slow bone resorption rates, thereby decreasing metastatic growth. [39] [40] [41] [42] Our study population is particularly fitting for this analysis. It has a long and complete follow-up of up to 22 years after diagnosis, and >93% participants are now deceased. The Swedish population consumes very high levels of dairy. In 1990, around the time of all prostate cancer diagnoses, Sweden had the second highest per-capita average dairy consumption in the world, 43 allowing us to study a wide range of dairy intake. This FFQ was validated and specific to the Swedish diet with a particularly comprehensive dairy section, decreasing potential for exposure misclassification. Dairy was assessed prospectively, eliminating differential reporting bias. We adjusted for many clinical and lifestyle variables, thus minimizing residual confounding. Because all participants were diagnosed before the introduction of PSA screening in Sweden, many were diagnosed with advanced prostate cancer, allowing us to stratify on clinical stage. Furthermore, there will be no bias due to PSA screening, which is often problematic in US analyses since PSA screening often correlates with dietary and lifestyle behavior.
Our study has also limitations. We ascertained dairy intake only at diagnosis, so we cannot directly assess patterns of intake over time. It is possible that prostate cancer may affect dietary habits, including dairy intake, both before and after diagnosis. However, because dairy was not considered to be associated with prostate cancer outcomes at that time, and because it remains a staple in the Swedish diet, it seems unlikely that men significantly changed their intake over time or after diagnosis. Nonetheless, this possibility represents a limitation of our study design. While the FFQ does not provide an exact measure of dairy intake, it adequately ranks intake across participants, which is sufficient for the objectives of our study. We do not have information on Gleason grade, a strong predictor of progression and mortality, but we do have information on tumor cell differentiation. Our sample size is relatively large considering we have ascertained outcomes on almost all patients, but analyses may still be underpowered to detect associations of smaller magnitude, reflected in the relatively large confidence intervals for many associations.
Our findings suggest that minimizing dairy intake may be an effective way to decrease prostate cancer progression and mortality. Specifically, whole milk may play a role in prostate cancer progression in cases diagnosed with localized prostate cancer. Our findings are generally consistent with existing studies on dairy intake and prostate cancer progression and mortality. However, further investigation on the mechanisms is warranted to identify which dairy components are responsible for this observed association.
